100th patient joins ChariotMS trial for multiple sclerosis
The trial is testing whether Mavenclad could benefit upper limb movement in MS patients
Read Moreby Jen Brogan | Nov 10, 2023 | News | 0
The trial is testing whether Mavenclad could benefit upper limb movement in MS patients
Read Moreby Jen Brogan | Oct 2, 2023 | News | 0
The study analysed and compared information from 65,000 MS patients
Read Moreby Jen Brogan | Aug 25, 2023 | News | 0
The disease-modifying therapy is approved to treat all indications covered by Tysabri
Read Moreby Jen Brogan | May 31, 2023 | News | 0
The neurological disease affects approximately 2.8 million people worldwide
Read Moreby Lucy Parsons | Nov 19, 2021 | News | 0
Vumerity is a next-generation oral fumarate treatment for adults with relapsing-remitting multiple sclerosis
Read Moreby Lucy Parsons | Nov 10, 2021 | News | 0
Janssen’s Ponvory accepted for use within NHS Scotland for adults RRMS patients
Read Moreby Lucy Parsons | Oct 13, 2021 | News | 0
Tolebrutinib reduced multiple sclerosis (MS) disease activity as measured by MRI
Read Moreby Lucy Parsons | Aug 11, 2021 | News | 0
Phase III trial showed a reduction in annual relapse rate
Read Moreby Lucy Parsons | Jun 23, 2021 | News | 0
B-cell targeting therapy preserved patients’ IgG/IgM levels, with no increased risk of serious infections
Read Moreby Lucy Parsons | Jun 21, 2021 | News | 0
Aubagio has been authorised for the treatment of paediatric patients aged ten to 17 years living with RRMS
Read Moreby Lucy Parsons | May 25, 2021 | News | 0
European approval follows the recent announcement of the FDA approval of Ponvory for RMS
Read Moreby Selina McKee | May 7, 2021 | News | 0
It is hoped that the multi-armed Octopus trial will rapidly speed up development of new treatments
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479